MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

42.01 0.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.55

Max

42.82

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-141M 3.1B
Eelmine avamishind	41.22
Eelmine sulgemishind	42.01

Uudiste sentiment

By Acuity

50%

141 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. jaan 2026, 23:49 UTC

Kuumad aktsiad

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26. jaan 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26. jaan 2026, 23:52 UTC

Market Talk

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26. jaan 2026, 23:37 UTC

Market Talk

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26. jaan 2026, 22:41 UTC

Market Talk

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26. jaan 2026, 22:26 UTC

Tulu

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26. jaan 2026, 22:26 UTC

Tulu

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26. jaan 2026, 22:25 UTC

Tulu

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26. jaan 2026, 22:24 UTC

Tulu

Karoon Energy 4Q Sales Revenue US$156.1 Million

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26. jaan 2026, 22:23 UTC

Tulu

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26. jaan 2026, 22:22 UTC

Tulu

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26. jaan 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Copper Shareholders Approve Takeover

26. jaan 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

26. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26. jaan 2026, 21:34 UTC

Tulu

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Sales $7.69B >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Net $378M >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26. jaan 2026, 21:30 UTC

Tulu

Nucor 4Q EPS $1.64 >NUE

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

29.53% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 29.53%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

141 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.